A groundbreaking new cancer trial is offering fresh hope to children and young people facing rare and aggressive cancers. The study, known as ‘Mighty’, will recruit up to sixty patients across the UK and the US to test CAR T-cell immunotherapy, a cutting-edge treatment which trains a patient’s own immune system to recognise and destroy cancer cells. With research centred at University College London, the trial focuses on cancers that are often resistant to conventional treatments. These include rhabdomyosarcoma, Ewing sarcoma, and other soft tissue sarcomas, which primarily affect children and young people. Researchers say that childhood cancers behave differently from adult cancers, requiring more targeted and less harmful treatments. CAR T-cell therapy has already shown promise in some blood cancers and is now being explored for solid tumours. Experts believe this innovative approach could significantly improve outcomes, offering renewed hope to families where existing treatments have failed or cancer has returned.